Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
MaxcyteMXCT | Open-market sale | 03/17 | 03/19 | 10,142 sh | $0.82 | $8,316.44 | −6.3% | |
Rekha HemrajaniDirector | MaxcyteMXCT | Open-market sale10b5-1 plan | 25/06/25 | 25/08/27 | 10,684 sh | $2.09 | $22,329.56 | −21.1% |
Richard DouglasDirector | MaxcyteMXCT | Open-market buy | 25/08/13 | 25/08/13 | 80,000 sh | $1.39 | $111,200 | +53.1% |
Stanley C. ErckDirector | MaxcyteMXCT | Open-market buy | 25/08/13 | 25/08/13 | 100,000 sh | $1.37 | $137,000 | +33.5% |
MaxcyteMXCT | Open-market buy | 25/08/13 | 25/08/13 | 50,000 sh | $1.29 | $64,500 | +44.7% | |
William W. BrookeDirector | MaxcyteMXCT | Open-market buy | 25/08/13 | 25/08/13 | 50,000 sh | $1.29 | $64,500 | +49.6% |
Maher MasoudPresident and CEO | MaxcyteMXCT | Open-market buy | 25/08/13 | 25/08/13 | 75,000 sh | $1.37 | $102,750 | +75.0% |
MaxcyteMXCT | Open-market sale | 25/03/18 | 25/03/20 | 6,939 sh | $3.18 | $22,066.02 | −5.8% | |
David I. SandovalGeneral Counsel | MaxcyteMXCT | Open-market sale | 25/03/18 | 25/03/20 | 353 sh | $3.18 | $1,122.54 | −0.5% |
Ali SoleymannezhadChief Commercial Officer | MaxcyteMXCT | Open-market sale | 25/03/18 | 25/03/20 | 1,211 sh | $3.18 | $3,850.98 | −2.0% |
John Joseph JohnstonDirector | MaxcyteMXCT | Open-market sale10b5-1 plan | 25/01/27 | 25/01/29 | 3,000 sh | $4.65 | $13,950 | −2.1% |
David I. SandovalGeneral Counsel | MaxcyteMXCT | Open-market sale | 25/01/13 | 25/01/14 | 4,466 sh | $4.54 | $20,275.64 | −9.7% |
John Joseph JohnstonDirector | MaxcyteMXCT | Open-market sale10b5-1 plan | 24/12/26 | 24/12/30 | 3,000 sh | $4.01 | $12,030 | −2.1% |
MaxcyteMXCT | Open-market sale10b5-1 plan | 24/12/06–24/12/09 | 24/12/10 | 3,000 sh2 trades | $3.77avg. | $11,324.55 | −2.1% | |
Stanley C. ErckDirector | MaxcyteMXCT | Open-market sale10b5-1 plan | 24/11/01 | 24/11/05 | 47,689 sh | $3.72 | $177,403.08 | −15.1% |
John Joseph JohnstonDirector | MaxcyteMXCT | Open-market sale10b5-1 plan | 24/10/28 | 24/10/30 | 3,000 sh | $3.72 | $11,160 | −2.1% |
MaxcyteMXCT | Open-market sale10b5-1 plan | 24/10/01–24/10/02 | 24/10/02 | 47,689 sh2 trades | $3.75avg. | $178,751.93 | −15.1% | |
John Joseph JohnstonDirector | MaxcyteMXCT | Open-market sale10b5-1 plan | 24/09/26 | 24/09/30 | 3,000 sh | $3.82 | $11,460 | −2.1% |
MaxcyteMXCT | Open-market sale10b5-1 plan | 24/09/03–24/09/04 | 24/09/05 | 47,689 sh2 trades | $4.02avg. | $191,655.19 | −15.1% | |
John Joseph JohnstonDirector | MaxcyteMXCT | Open-market sale10b5-1 plan | 24/08/26 | 24/08/28 | 3,000 sh | $4.28 | $12,840 | −2.1% |